Timothy Rolph, the Chief Scientific Officer of $AKRO ($AKRO), sold 2,450 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing ...

The put/call ratio of AKRO is 1.50, indicating a bearish outlook ... Akero Therapeutics Background Information (This description is provided by the company.) Akero Therapeutics is a clinical ...